We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Autonomous Microchannel Analyzer Combines with Smartphone for Off-Site Disease Diagnostics

By LabMedica International staff writers
Posted on 18 Feb 2020
A novel microchannel capillary flow assay platform for detection of pathogenic microorganisms or other antigens combines with a smartphone for display, data transfer, storage, and analysis.

Investigators at the University of Cincinnati (OH, USA) built the microchannel capillary flow assay (MCFA) platform to perform chemiluminescence based ELISA tests with lyophilized chemiluminescent reagents. More...
The MCFA platform exploits the ultra-high sensitivity of chemiluminescent detection while eliminating the shortcomings associated with liquid reagent handling, control of assay sequence, and user intervention.

Functionally designed microchannels along with adequate hydrophilicity provided by the saliva sample produce a sequential flow of assay reagents, and the device autonomously performs the ultra-high sensitive chemiluminescence based ELISA. An attached smartphone for display, data transfer, storage and analysis, as well as the source of power, enabled the development of a point-of-care-testing (POCT) analyzer for disease diagnostics.

The current report described the use of the MCFA device for detection of the malaria biomarker PfHRP2. For this antigen a limit of detection (LOD) of eight nanograms per milliliter was achieved, which is sensitive enough to detect active malarial infection.

Furthermore, the investigators assert that the device can be adapted to diagnose other infectious diseases such as coronavirus, HIV or Lyme disease or innumerable other health conditions such as depression and anxiety.

"The performance is comparable to laboratory tests. The cost is cheaper. And it is user-friendly," said senior author Dr. Chong Ahn, distinguished university research professor at the University of Cincinnati. "We wanted to make it simple so anyone could use it without training or support. Right now it takes several hours or even days to diagnose in a lab, even when people are showing symptoms. The disease can spread."

The MCFA device was described in the January 27, 2020, online edition of the journal Microsystems & Nanoengineering.

Related Links:
University of Cincinnati


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.